About Bioscience Valuation
Bioscience Valuation was founded in the year 2000. At that time it became increasingly important to demonstrate value propositions to inform rational investment decisions by owners and investors, taking advantage of all available information and using advanced R&D, commercial and financial modeling. Bioscience Valuation provides these services to many successful clients.
Today, pharmaceutical companies face equally challenging times characterized by decreasing R&D productivity and higher hurdles to gain market access. The future will be shaped by advancing personalized treatments, taking companion-diagnostic, genomic and proteomic information into account. This creates economic challenges on its own.
"We combine in-depth commercial, R&D, economic and financial expertise with analytic capabilities that are second to none, and we use our strengths to enable senior management to achieve its goals. We do so by generating validated, fact-based evidence that forms the basis for persuasive arguments and convincing communications."
Joachim M. Greuel, Ph.D., MBA, Co-Founder and Managing Director
Bioscience Valuation is a member of
- the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), USA,
- the Personalized Medicine Coalition (PMC), USA,
- the American Finance Association, USA.